Follow the people · Insider
Nancy C. Andrews
Nancy C. Andrews files insider transactions with the SEC as a director of Charles River Laboratories International (CRL). We hold 1 disclosed purchase or sale filed since 4 March 2020, 1 of them in the last 90 days.
- Files forCRL
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure20 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 2 March 2020 — 18 August 2026Director · Charles River Laboratories International (CRL)20 Form 4 lines · source: SEC Form 4
- Filed 22 September 2025 — 8 June 2026Director · Maze Therapeutics (MAZE)2 Form 4 lines · source: SEC Form 4
Everything they disclosed
22 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 573 shares of Charles River Laboratories InternationalSEC Form 420 August 2026Common Stock · traded 18 August 2026 · filed 20 August 2026
- ▼ sold on the open market 573 shares of Charles River Laboratories InternationalSEC Form 420 August 2026Common Stock · traded 18 August 2026 · filed 20 August 2026
- exercised options over 573 shares of Charles River Laboratories International (a derivative holding)SEC Form 420 August 2026Stock Options (Right to Buy) · traded 18 August 2026 · filed 20 August 2026
- was granted 18,000 shares of Maze Therapeutics (a derivative holding)SEC Form 410 June 2026Stock Option (Right to Buy) · traded 8 June 2026 · filed 10 June 2026
- gave away 3,964 shares of Charles River Laboratories InternationalSEC Form 414 May 2026Common Stock · traded 12 May 2026 · filed 14 May 2026
- gave away 3,964 shares of Charles River Laboratories InternationalSEC Form 414 May 2026Common Stock · traded 12 May 2026 · filed 14 May 2026
- was granted 1,438 shares of Charles River Laboratories InternationalSEC Form 411 May 2026Common Stock · traded 8 May 2026 · filed 11 May 2026
- was granted 18,000 shares of Maze Therapeutics (a derivative holding)SEC Form 424 September 2025Stock Option (Right to Buy) · traded 22 September 2025 · filed 24 September 2025
- was granted 2,076 shares of Charles River Laboratories International (a derivative holding)SEC Form 423 May 2025Stock Options (Right to Buy) · traded 21 May 2025 · filed 23 May 2025
- was granted 946 shares of Charles River Laboratories InternationalSEC Form 423 May 2025Common Stock · traded 21 May 2025 · filed 23 May 2025
- was granted 1,311 shares of Charles River Laboratories International (a derivative holding)SEC Form 415 May 2024Stock Options (Right to Buy) · traded 13 May 2024 · filed 15 May 2024
- was granted 559 shares of Charles River Laboratories InternationalSEC Form 415 May 2024Common Stock · traded 13 May 2024 · filed 15 May 2024
- was granted 1,669 shares of Charles River Laboratories International (a derivative holding)SEC Form 417 May 2023Stock Options (Right to Buy) · traded 15 May 2023 · filed 17 May 2023
- was granted 664 shares of Charles River Laboratories InternationalSEC Form 417 May 2023Common Stock · traded 15 May 2023 · filed 17 May 2023
- was granted 1,582 shares of Charles River Laboratories International (a derivative holding)SEC Form 413 May 2022Stock Options (Right to Buy) · traded 11 May 2022 · filed 13 May 2022
- was granted 575 shares of Charles River Laboratories InternationalSEC Form 413 May 2022Common Stock · traded 11 May 2022 · filed 13 May 2022
- was granted 355 shares of Charles River Laboratories InternationalSEC Form 410 May 2021Common Stock · traded 7 May 2021 · filed 10 May 2021
- was granted 1,151 shares of Charles River Laboratories International (a derivative holding)SEC Form 410 May 2021Stock Options (Right to Buy) · traded 7 May 2021 · filed 10 May 2021
- was granted 2,539 shares of Charles River Laboratories International (a derivative holding)SEC Form 412 May 2020Stock Options (Right to Buy) · traded 11 May 2020 · filed 12 May 2020
- was granted 741 shares of Charles River Laboratories InternationalSEC Form 412 May 2020Common Stock · traded 11 May 2020 · filed 12 May 2020
- was granted 573 shares of Charles River Laboratories International (a derivative holding)SEC Form 44 March 2020Stock Options (Right to Buy) · traded 2 March 2020 · filed 4 March 2020
- was granted 124 shares of Charles River Laboratories InternationalSEC Form 44 March 2020Common Stock · traded 2 March 2020 · filed 4 March 2020
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.